Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma

Yoshizaki, Tomokazu; Maruyama, Yumiko; Sato, Hiroshi; Furukawa, Mitsuru

doi:10.1002/1097-0215(20010120)95:1<44::aid-ijc1008>3.0.co;2-m

Cited by 119 publications

(69 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In pancreatic carcinomas Koshiba et al (1998) reported that the MMP-2 activation ratio in pT3 tumors is significantly higher than that in pT1 tumors, and that the MMP-2 activation ratio is significantly higher in lymph node metastasis and distant metastasis cases than cases without metastasis. Regarding squamous cell carcinoma of the tongue Yoshizaki et al (2001) reported that activation of MMP-2 predicts poor prognosis of the patients. Thus our finding that activation of MMP-2 is associated with an unfavorable clinical outcome in OSCC patients is in accord with these previous reports.…”

Section: Discussionmentioning

confidence: 99%

Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity

Kato

Hara

Kuno

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

These results indicate that two types of proform and activated form matrix metalloproteinases, MMP-2 and MMP-9, are present in human OSCC, and that the activated MMP-2 could be a main enzymatic activity of gelatinolysis in OSCC. Interaction of tumor cells and stromal cells seems to play an important role in the invasion and metastasis of human OSCC. Combination analysis of zymography and FIZ is a useful method to detect activity and localization of MMPs in human OSCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity

Kato

Hara

Kuno

et al. 2004

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…After reviewing the full text of the remaining 21 studies, we ultimately included 11 studies [11][12][13][14][15][16][17][18][19][20][21] in the final analysis. Ten studies were excluded from the final review for these reasons: (1) insufficient survival data (n=8) [23][24][25][26][27][28][29][30] and (2) MT1-MMP expression was not measured by immunohistochemistry (n =2) [31,32]. Figure 1 shows a flow diagram with the numbers of relevant studies.…”

Section: Eligible Studiesmentioning

confidence: 99%

“…Some studies indicated that positive MT1-MMP expression was significantly associated with a poor prognosis [11, 13-22, 24, 27, 28, 30, 31], while others did not agree [12,19,23,25,26,29]. We therefore performed a meta-analysis aiming to evaluate the relationship between MT1-MMP expression and prognosis in patients with multiple cancers.…”

Section: Introductionmentioning

confidence: 99%

MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies

Lin

et al. 2014

Tumor Biol.

View full text Add to dashboard Cite

MT1-MMP exhibits diverse expressions in patients with cancer and could be considered as potential prognostic biomarker of cancer. We performed a meta-analysis aiming to provide more sufficient evidence that MT1-MMP expression is associated with poor overall survival in several types of cancers. We systematically searched the studies from databases and carefully identified based on eligibility criteria. The association between MT1-MMP expression and overall survival in cancers was estimated using Review Manager. A total of 11 literatures which included 1,918 cancer patients were combined in the final analysis. Meta-analysis revealed that MT1-MMP overexpression was associated with an unfavorable overall survival and the pooled hazard ratio (HR) and corresponding 95 % confidence interval (CI) was 2.46 (95 % CI 1.75-3.47). From subgroup analyses, we identified that MT1-MMP was an independent prognostic factor for lung cancer and gastric cancer, and HRs (95 % CI) were 3.73 (95 % CI 2.67-5.21) and 2.46 (95 % CI 1.69-3.59), respectively. In conclusion, MT1-MMP is a potential prognostic factor in human cancers.

show abstract

“…Elevated levels of distinct MMPs can be detected in tumor tissueserum, or even urine of patients with advanced cancer, and their role as predicting marker in cancer metastatic recurrence has been studied (Gerhards et al 2001;Ranuncolo et al 2003;Rao 2003;Sasaki et al 2002;Vihinen et al 2002). MMP-2 is the most important enzyme in the process of ECM remodeling involved in tumor invasion and metastasis, and could serve as a marker for shortened recurrence-free survival or relative overall survival in patients with carcinomas of breast (Talvensaari-Mattila et al 2003), lung (Cai et al 2002Sienel et al 2003), head and neck (Ondruschka et al 2002), thyroid (Patel et al 2002), tongue (Yoshizaki et al 2001), superficial transitional cell (Hara et al 2001), and bladder (Papathoma et al 2000).…”

Section: Matrix Metalloproteinases (Mmps)mentioning

confidence: 99%

Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

Qin

Tang

2004

J Cancer Res Clin Oncol

173

148

View full text Add to dashboard Cite

Molecular markers (biomarkers) for hepatocellular carcinoma (HCC) metastasis and recurrence could provide additional information to that gained from traditional histopathological features. A large number of biomarkers have been shown to have potential predictive significance. One important aspect of this is to detect the transcripts of tumor-associated antigens (such as AFP, MAGEs, and CK19), which are proposed as predictive markers of HCC cells disseminated into the circulation and for metastatic recurrence. Another important aspect is to analyze the molecular markers for cellular malignancy phenotype, including DNA ploidy, cellular proliferation index, cell cycle regulators, oncogenes, and tumor suppressors (especially p53 gene), as well as telomerase activity. Molecular factors involved in the process of HCC invasion and metastasis, including adhesion molecules (E-cadherin, catenins, ICAM-1, laminin-5, CD44 variants, osteopontin), proteinases responsible for the degradation of extracellular matrix (MMPs, uPA system), as well as angiogenesis regulators (such as VEGF, intratumor MVD), have also been shown to be potential predictors for HCC metastatic recurrence and clinical outcomes. One important new trend is to widely delineate biomarkers with genomic and proteomic expression with reference to predicting metastatic recurrence, molecular diagnosis, and classification, which has been drawing more attention recently. Body fluid (particularly blood and urine) testing for biomarkers is easily accessible and more useful in clinical patients. The prognostic significance of circulating DNA in plasma or serum and its genetic alterations is another important direction. More attention should be paid to these areas in the future. As understanding of tumor biology deepens, more and more new biomarkers with high sensitivity and specificity for HCC metastatic recurrence could be found and routinely used in clinical assays. However, the combination of the pathological features and some of the biomarkers mentioned above seems to be more practical up to now.

show abstract

Expression of tissue inhibitor of matrix metalloproteinase-2 correlates with activation of matrix metalloproteinase-2 and predicts poor prognosis in tongue squamous cell carcinoma

Cited by 119 publications

References 21 publications

Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity

Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: manifestation and localization of their activity

MT1-MMP is not a good prognosticator of cancer survival: evidence from 11 studies

Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature

Contact Info

Product

Resources

About